EBMT-EHA CAR-T 2019 | The role of the EBMT regarding CAR T-cell therapy
Christian Chabannon, MD, PhD, of Paoli-Calmettes Institute, Marseille, France, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA). Prof. Chabannon speaks on the importance of the EBMT in the rolling out of CAR T-cell therapy, specifically it’s registry that captures data on patients treated with the treatment. Prof. Chabannon goes on to discuss the two pillars of the EBMT strategy: education and accreditation with specific standards being put in place to qualify centers to use CAR T-cell therapy, and the use of events such as the EBMT-EHA CAR T-Cell Meeting to educate investigators in the field.
Transcript (edited for clarity)
EBMT originally was a professional association created to evaluate and promote the use of stem cell transplantation. And although CAR-T cells are different because they represent the transfer of cellular therapies to the industry in many aspects, they also raise and create common problems with stem cell transplantation. And in particular, EBMT has a very important asset, which is its registry, and the registry will be used in the future to register and to capture the data for patients treated with CAR T-cells. There are ongoing discussions with the European Medicines Agency, EMA, to qualify the EBMT registry. We are talking with the major industry players in the field to capture data for patients treated with these new treatments. And the two pillars in the EBMT strategy are education and accreditation. Accreditation based on fact and JACIE standards. We are designing a specific set of standards to be used with the immune effector cells therapy independently of transplant activity, and this could be used as one of the criteria to qualify centers for CAR T-cells administrations. And obviously, education, this meeting is a very good example of the initiatives that EBMT is promoting together with the other interested parties, such as the European Hematology Association, EHA, to bring knowledge and experience to European investigators in this new field.
Read more...
